253 related articles for article (PubMed ID: 7962990)
1. Beta-lactamases: current situation and clinical importance.
Garau J
Intensive Care Med; 1994 Jul; 20 Suppl 3():S5-9. PubMed ID: 7962990
[TBL] [Abstract][Full Text] [Related]
2. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
[TBL] [Abstract][Full Text] [Related]
3. beta-Lactam susceptibility patterns and investigation of cephalosporin hydrolysing beta-lactamases of Gram-negative extraintestinal clinical isolates.
Gál Z; Szabó D; Kovács P; Hernádi F; Tóth-Martinez B; Rozgonyi F
Int J Antimicrob Agents; 2000 Dec; 16(4):395-400. PubMed ID: 11118847
[TBL] [Abstract][Full Text] [Related]
4. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases.
Neu HC
Am J Med; 1985 Nov; 79(5B):2-12. PubMed ID: 3907341
[TBL] [Abstract][Full Text] [Related]
5. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
Susić E
Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
[TBL] [Abstract][Full Text] [Related]
6. beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact.
Sanders CC; Sanders WE
Clin Infect Dis; 1992 Nov; 15(5):824-39. PubMed ID: 1445981
[TBL] [Abstract][Full Text] [Related]
7. Characteristics, epidemiology and clinical importance of emerging strains of Gram-negative bacilli producing extended-spectrum beta-lactamases.
Shah AA; Hasan F; Ahmed S; Hameed A
Res Microbiol; 2004; 155(6):409-21. PubMed ID: 15249058
[TBL] [Abstract][Full Text] [Related]
8. Emergence of resistance in gram-negative bacteria: a risk of broad-spectrum beta-lactam use.
Dworzack DL
Drug Intell Clin Pharm; 1986; 20(7-8):562-7. PubMed ID: 3488894
[TBL] [Abstract][Full Text] [Related]
9. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.
Bradford PA
Clin Microbiol Rev; 2001 Oct; 14(4):933-51, table of contents. PubMed ID: 11585791
[TBL] [Abstract][Full Text] [Related]
10. Clinical importance of inducible beta-lactamases in gram-negative bacteria.
Sanders CC; Sanders WE
Eur J Clin Microbiol; 1987 Aug; 6(4):435-8. PubMed ID: 3311737
[TBL] [Abstract][Full Text] [Related]
11. A perspective on the present contribution of beta-lactamases to bacterial resistance with particular reference to induction of beta-lactamase and its clinical significance.
Neu HC; Chin NX
Chemioterapia; 1985 Feb; 4(1):63-70. PubMed ID: 3872725
[TBL] [Abstract][Full Text] [Related]
12. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
Ko WC; Hsueh PR
J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
[TBL] [Abstract][Full Text] [Related]
13. Minor extended-spectrum beta-lactamases.
Naas T; Poirel L; Nordmann P
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():42-52. PubMed ID: 18154527
[TBL] [Abstract][Full Text] [Related]
14. Sch 34343, in-vitro antibacterial activity and beta-lactamase stability.
Stobberingh EE; Houben AW; van Boven CP
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():73-83. PubMed ID: 3875605
[TBL] [Abstract][Full Text] [Related]
15. Sch 34343: in-vitro antibacterial activity and susceptibility to beta-lactamases.
Shannon K; King A; Phillips I
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():15-23. PubMed ID: 3897169
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and Management of Emerging Drug-Resistant Gram-Negative Bacteria: Extended-Spectrum β-Lactamases and Beyond.
Boyle DP; Zembower TR
Urol Clin North Am; 2015 Nov; 42(4):493-505. PubMed ID: 26475946
[TBL] [Abstract][Full Text] [Related]
17. [The growing problem of antibiotic resistance in clinically relevant Gram-negative bacteria: current situation].
Martínez-Martínez L; Calvo J
Enferm Infecc Microbiol Clin; 2010 Sep; 28 Suppl 2():25-31. PubMed ID: 21130927
[TBL] [Abstract][Full Text] [Related]
18. IRT and CMT beta-lactamases and inhibitor resistance.
Cantón R; Morosini MI; de la Maza OM; de la Pedrosa EG
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():53-62. PubMed ID: 18154528
[TBL] [Abstract][Full Text] [Related]
19. Comparable evaluation of orally active beta-lactam compounds in ampicillin-resistant gram-positive and gram-negative rods: role of beta-lactamases on resistance.
Cullmann W; Dick W; Stieglitz M; Opferkuch W
Chemotherapy; 1988; 34(3):202-15. PubMed ID: 3262045
[TBL] [Abstract][Full Text] [Related]
20. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
Medeiros AA; Hare R; Papa E; Adam C; Miller GH
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
